Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised “hundreds of millions” of renminbi in a Series B+ financing round. The funding was led by Lotus Lake Capital and Kangyu Capital, with participation from existing investor Qiming Venture Partners. The proceeds will be used to support clinical trials, expand the product pipeline, build a market team, and enhance overall operations.
Company Overview and Pipeline
Founded in 2017, Singular Medical has established itself as a leader in the development of advanced cardiac devices. The company’s product pipeline includes an implantable cardioverter defibrillator (ICD), a new pacing system, an implantable and wearable heart monitoring system, and a digital arrhythmia cloud platform. These innovations aim to improve the management and treatment of cardiac conditions, particularly in the areas of rhythm management and heart failure.
Global R&D Presence
Singular Medical, headquartered in Suzhou, has strategically established research and development (R&D) centers in Beijing and California, alongside a key process R&D and small batch production center in Minnesota. This global R&D footprint underscores the company’s commitment to innovation and its ability to leverage diverse expertise and resources.
Future Outlook
The Series B+ financing round positions Singular Medical to accelerate its growth and expand its market reach. With robust financial backing and a strong product pipeline, the company is poised to make a significant impact in the cardiac device market. Singular Medical’s ongoing efforts in clinical trials and product development highlight its dedication to improving patient outcomes through innovative solutions.-Fineline Info & Tech
